Occupational Activity – Page 2

J&J brushes off tariff headwinds with raised forecast, oncology surge

1 week ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Merck inks $493M biobucks deal to use Cyprumed’s tech to create oral peptides

1 week ago talkbio0Tagged biobucks, Cyprumed, Merck, Peptides

Cyprumed, Merck, biobucks, Peptides

Harvard Faces $2.2 Billion Federal Funding Freeze After Defying Trump Administration Demands

1 week ago talkbio0Tagged Academia (organization), Administration occupational activities, antisemitism, battle, campus, civil, DEI, Diversity, federal, Freezing, Harvard University, Legal, protest, Research Projects, R-Series, Status, Transplant Registry Unified Management Program, university governance

Harvard University, Trump administration, federal funding freeze, $2.2 billion, research grants, diversity equity inclusion (DEI), antisemitism, academic independence, campus protests, Title VI, civil rights, university governance, legal battle, tax exempt status

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives

1 week ago talkbio0Tagged 90%, Interleukin-2, Mural, Mural Oncology, Nemvaleukin Alfa, strategic alternatives

Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%

Biopharma Layoff Trends in Q1 2025 and Outlook for Q2

2 weeks ago talkbio0Tagged Biopharma, Biopharma layoffs, Changing, Industry, Legal patent, Pharma, pharmaceutical employment, Q1 2025, Q2 layoff, regulatory, restructuring

Biopharma layoffs, Q1 2025 layoffs, biotech job cuts, pharma workforce reductions, restructuring, patent cliffs, regulatory challenges, Q2 layoff forecast, pharmaceutical employment trends, biopharma industry changes.

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

2 weeks ago talkbio0Tagged biotech, Clinical Trial Failures, Cost savings programs, Glycogen storage disease type II, Industry, Opthea layoffs, Pfizer, Pfizer staff, Pharma, restructuring

Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges

Novartis to invest $23B in manufacturing so ‘all key medicines’ can be made in the US

2 weeks ago talkbio0Tagged Biological Factors, Investments, Manufacture, Novartis, production, United States

Novartis, United States, Investments, Manufacture, production, Biological Factors, Novartis

Appeals Court Blocks Reinstatement of Fired Federal Probationary Workers, Affecting 20 Agencies

2 weeks ago talkbio0Tagged Administration occupational activities, Appeals court decision, Employee, federal, Federal reduction-in-force statute, firings, Supreme Court stay, Transplant Registry Unified Management Program, Worker

Federal probationary workers, Appeals court decision, Trump administration, Worker reinstatement halt, Federal reduction-in-force statute, Supreme Court stay, Probationary employee firings

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

2 weeks ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.

Pharma stocks swerve as Trump hits pause on most tariffs

2 weeks ago talkbio0Tagged Market, Pauses, Transplant Registry Unified Management Program

Market, Transplant Registry Unified Management Program, Pauses